Alnylam Pharmaceuticals, Inc. (BVMF:A1LN34)

Alnylam Pharmaceuticals Statistics

Total Valuation

BVMF:A1LN34 has a market cap or net worth of BRL 316.76 billion. The enterprise value is 317.02 billion.

Market Cap	316.76B
Enterprise Value	317.02B

Important Dates

The last earnings date was Thursday, November 6, 2025.

Earnings Date	Nov 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+4.82%
Shares Change (QoQ)	+5.14%
Owned by Insiders (%)	0.32%
Owned by Institutions (%)	100.65%
Float	130.24M

Valuation Ratios

The trailing PE ratio is 1,364.31 and the forward PE ratio is 47.14.

PE Ratio	1,364.31
Forward PE	47.14
PS Ratio	18.52
PB Ratio	254.12
P/TBV Ratio	254.12
P/FCF Ratio	268.50
P/OCF Ratio	223.56
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 155.05, with an EV/FCF ratio of 268.72.

EV / Earnings	1,365.42
EV / Sales	18.65
EV / EBITDA	155.05
EV / EBIT	226.15
EV / FCF	268.72

Financial Position

The company has a current ratio of 2.54, with a Debt / Equity ratio of 11.86.

Current Ratio	2.54
Quick Ratio	2.37
Debt / Equity	11.86
Debt / EBITDA	7.18
Debt / FCF	12.53
Interest Coverage	1.63

Financial Efficiency

Return on equity (ROE) is 32.73% and return on invested capital (ROIC) is 5.74%.

Return on Equity (ROE)	32.73%
Return on Assets (ROA)	3.65%
Return on Invested Capital (ROIC)	5.74%
Return on Capital Employed (ROCE)	8.03%
Revenue Per Employee	7.67M
Profits Per Employee	104,114
Employee Count	2,230
Asset Turnover	0.71
Inventory Turnover	6.83

Taxes

Income Tax	-402.41M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +47.15% in the last 52 weeks. The beta is 0.30, so BVMF:A1LN34's price volatility has been lower than the market average.

Beta (5Y)	0.30
52-Week Price Change	+47.15%
50-Day Moving Average	123.20
200-Day Moving Average	95.75
Relative Strength Index (RSI)	48.93
Average Volume (20 Days)	153

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.36

Income Statement

In the last 12 months, BVMF:A1LN34 had revenue of BRL 17.11 billion and earned 232.18 million in profits. Earnings per share was 1.76.

Revenue	17.11B
Gross Profit	14.35B
Operating Income	1.41B
Pretax Income	-170.24M
Net Income	232.18M
EBITDA	1.71B
EBIT	1.41B
Earnings Per Share (EPS)	1.76

Balance Sheet

The company has 14.52 billion in cash and 14.78 billion in debt, giving a net cash position of -259.46 million.

Cash & Cash Equivalents	14.52B
Total Debt	14.78B
Net Cash	-259.46M
Net Cash Per Share	n/a
Equity (Book Value)	1.25B
Book Value Per Share	9.46
Working Capital	12.78B

Cash Flow

In the last 12 months, operating cash flow was 1.42 billion and capital expenditures -237.15 million, giving a free cash flow of 1.18 billion.

Operating Cash Flow	1.42B
Capital Expenditures	-237.15M
Free Cash Flow	1.18B
FCF Per Share	n/a

Margins

Gross margin is 83.90%, with operating and profit margins of 8.25% and 1.36%.

Gross Margin	83.90%
Operating Margin	8.25%
Pretax Margin	-1.00%
Profit Margin	1.36%
EBITDA Margin	10.00%
EBIT Margin	8.25%
FCF Margin	6.90%

Dividends & Yields

BVMF:A1LN34 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.82%
Shareholder Yield	-4.82%
Earnings Yield	0.07%
FCF Yield	0.37%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BVMF:A1LN34 has an Altman Z-Score of 4.46 and a Piotroski F-Score of 5.

Altman Z-Score	4.46
Piotroski F-Score	5